34 results
8-K
EX-99.1
IVVD
Invivyd Inc
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
confidence in the deep expertise of the entire Adagio team as we move to our next phase of long-term success and growth. We look forward to providing
8-K
EX-99.1
IVVD
Invivyd Inc
29 Jun 23
Other Events
7:08am
Infectious Diseases 2023 6
WE BELIEVE PREVENTION OF COVID-19 IN VULNERABLE POPULATIONS IS A LONG-TERM, POTENTIALLY LARGE OPPORTUNITY $2.2B in total revenue … populations, such as immunocompromised people, with protection from COVID-19 is a long-term, large opportunity Invivyd is executing on its strategy
8-K
EX-99.1
IVVD
Invivyd Inc
11 Sep 23
Other Events
7:10am
; 3. Marzolini Clin Pharmacol Ther 2022 6
PREVENTION OF COVID-19 IN VULNERABLE POPULATIONS PRESENTS A COMPELLING, POTENTIAL LONG-TERM VALUE … COVID-19 is a compelling, potential long-term value proposition Invivyd is rapidly executing on its VYD222 clinical development plan, with positive
8-K
EX-99.1
IVVD
Invivyd Inc
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
leadership team,” said René Russo, Pharm.D., co-founder and chairman of Adagio. “To support our long-term growth, we have initiated a formal CEO
8-K
EX-99.1
IVVD
Invivyd Inc
15 Aug 22
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
7:22am
in the first quarter of 2023. We look forward to sharing updates on the company and our long-term strategy, as well as the progress across our
8-K
EX-99.1
ozcvqvghaam jecd
2 May 23
Departure of Directors or Certain Officers
7:37am
8-K
EX-99.3
21f5pd
12 Sep 22
Adagio Therapeutics Announces Corporate Name Change to Invivyd
7:46am
10-K/A
hla4sztgxq6dz8m
29 Apr 22
Annual report (amended)
4:43pm
8-K
EX-10.1
y574 gioycja4
22 Dec 23
Entry into a Material Definitive Agreement
4:53pm
PRER14C
2uiv0ph1 ir61h
31 May 22
Preliminary revised information
5:09pm
PREC14C
l366yw7
19 May 22
Preliminary information statement in contested solicitation
5:05pm
DEFC14C
htftz5c7ymgm
2 Jun 22
Information statement in contested solicitation
4:24pm
PREC14A
s7asfz
26 Apr 22
Preliminary proxy with contested solicitation
8:48am
PREC14A
0marb3derqco5
11 Apr 22
Preliminary proxy with contested solicitation
6:44am
PRE 14A
raxdv 55wl
31 Mar 23
Preliminary proxy
4:36pm
DEF 14A
ri4xcszmzh
10 Apr 23
Definitive proxy
4:07pm
10-K
pknjbt
31 Mar 22
Annual report
8:18am
PRRN14A
lcbtnvoaeggir aouht
25 Apr 22
Revised preliminary proxy statement filed by non-management
5:23pm
8-K
EX-99.1
msing ujx
9 Feb 24
Index to Consolidated Financial Statements
4:01pm